Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
  • Page of 1
McCollum AK, Casagrande G, Kohn EC. Caught in the middle: the role of Bag3 in disease. Biochem J. 2009 Dec 14;425(1):e1-3. doi: 10.1042/BJ20091739. PubMed PMID: 20001957; PubMed Central PMCID: PMC7291699.
McCollum AK, Lukasiewicz KB, Teneyck CJ, Lingle WL, Toft DO, Erlichman C. Cisplatin abrogates the geldanamycin-induced heat shock response. Mol Cancer Ther. 2008 Oct;7(10):3256-64. doi: 10.1158/1535-7163.MCT-08-0157. PubMed PMID: 18852129; PubMed Central PMCID: PMC2572571.
McCollum AK, TenEyck CJ, Stensgard B, Morlan BW, Ballman KV, Jenkins RB, Toft DO, Erlichman C. P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response. Cancer Res. 2008 Sep 15;68(18):7419-27. doi: 10.1158/0008-5472.CAN-07-5175. PubMed PMID: 18794130; PubMed Central PMCID: PMC2695926.
Yu C, Friday BB, Lai JP, McCollum A, Atadja P, Roberts LR, Adjei AA. Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation. Clin Cancer Res. 2007 Feb 15;13(4):1140-8. doi: 10.1158/1078-0432.CCR-06-1751. PubMed PMID: 17317822.
McCollum AK, Teneyck CJ, Sauer BM, Toft DO, Erlichman C. Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism. Cancer Res. 2006 Nov 15;66(22):10967-75. doi: 10.1158/0008-5472.CAN-06-1629. PubMed PMID: 17108135.
Nowakowski GS, McCollum AK, Ames MM, Mandrekar SJ, Reid JM, Adjei AA, Toft DO, Safgren SL, Erlichman C. A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6087-93. doi: 10.1158/1078-0432.CCR-06-1015. PubMed PMID: 17062684.
What would you like to do?
  • Page of 1